Disease Info Card

Telomere Shortening

Information about Telomere Shortening: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Telomere Shortening

Most recent studies have shown that Telomere Shortening shares some biological mechanisms with adenocarcinoma, anemia, carcinogenesis, carcinoma, cardiovascular-diseases, cell-transformation-neoplastic, cytogenetic-abnormality, diabetes-mellitus, dyskeratosis, dyskeratosis-congenita, genomic-instability, growth-arrest, inflammation, instabilities-chromosomal, leukemia, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasms, pancytopenia, premature-aging-syndrome.

Among the many pathways, these few ones have gauged particular interests from scientists studying Telomere Shortening, and have been seen in publications frequently: Aging, Anaphase, Cell Aging, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Division, Cell Growth, Cell Proliferation, Cellular Senescence, Dna Repair, Dna Replication, Metaphase, Methylation, Mitosis, Pathogenesis, Regeneration, Replicative Senescence, Senescence, Telomere Maintenance

Quite a number of genes have been found to play important roles in Telomere Shortening, such as ATM, CDKN1A, CDKN2A, GLB1, IL5, NSG1, PAK3, PARP1, RB1, SCYL1, TBPL1, TCEAL1, TERF1, TERF2, TERT, TP53, XRCC5. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.